Video
Dr. Garmezy on the evolving treatment paradigm for progressive urothelial malignancies
Author(s):
“There has been a ton of activity in recent years with new FDA approvals,” says Benjamin Garmezy, MD.
Video Player is loading.
In this video, Benjamin Garmezy, MD, discusses the expanding armamentarium for the treatment of patients with progressive urothelial malignancies. Garmezy is assistant director of Genitourinary Research at Sarah Cannon Research Institute at Tennessee Oncology.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Related Videos
Related Content
